Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Hydrocortison · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Arm 1 | EXPERIMENTAL | - |
| Arm 2 | EXPERIMENTAL | - |
| Arm 3 | OTHER | - |
| Name | Type | Description |
|---|---|---|
| Sinecort cream | DEVICE | Application over 29 days |
| Hydrocortison cream | DRUG | Application over 29 days |
| Untreated skin | OTHER | - |
Inclusion Criteria: * Male or female Caucasians aged between 18 and 65 years * Patients with mild AD presenting a scoring AD (SCORAD) rating between 3-25 * Skin type I - IV according to Fitzpatrick * Acute AD symptoms on each assessment areas (local SCORAD \>/=3 and \<= 12) * Acute symptom of pruri...
Top 20 of 25 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| AbbVie, Inc. | ABBV | 9 | PHASE3 | Upadacitinib, corticosteroids |
| Pfizer Inc. | PFE | 11 | PHASE3 | Abrocitinib |
| Eli Lilly and Company | LLY | 4 | PHASE3 | Lebrikizumab, Corticosteroid |
| Sanofi SA Sponsored ADR | SNY | 13 | PHASE3 | Amlitelimab |
| Regeneron Pharmaceuticals, Inc. | REGN | 4 | PHASE3 | Dupilumab |
| Incyte Corporation | INCY | 3 | PHASE3 | Ruxolitinib, Vehicle |
| Organon & Co. | OGN | 1 | PHASE3 | Tapinarof, 1%, Vehicle |
| Apogee Therapeutics, Inc. | APGE | 3 | PHASE2 | APG777 |
| Novartis AG Sponsored ADR | NVS | 2 | PHASE2 | GIA632 |
| Johnson & Johnson | JNJ | 1 | PHASE2 | JNJ-95597528 |
| Kymera Therapeutics, Inc. | KYMR | 1 | PHASE2 | KT-621 |
| Corvus Pharmaceuticals, Inc. | CRVS | 1 | PHASE2 | Soquelitinib |
| Nektar Therapeutics | NKTR | 1 | PHASE2 | Rezpegaldesleukin |
| Celldex Therapeutics, Inc. | CLDX | 1 | PHASE2 | Barzolvolimab |
| Evommune, Inc. | EVMN | 1 | PHASE2 | EVO756 |
| Sunshine Biopharma Incorporated | SBFM | 3 | PHASE3 | 611, corticosteroid |
| Aclaris Therapeutics, Inc. | ACRS | 1 | PHASE2 | ATI-045 |
| Q32 Bio Inc | QTTB | 1 | PHASE2 | ADX-914 |
| Turn Therapeutics Inc. | TTRX | 1 | PHASE2 | GX-03 |
| Arcutis Biotherapeutics Inc | ARQT | 1 | PHASE1 | ARQ-234 |
Hydrocortison is a small molecule being developed for the treatment of atopic dermatitis, a chronic inflammatory skin condition. It is currently in Phase 2 clinical development and is being studied as an investigational therapy for this indication.
Hydrocortison is being developed by Bayer AG, a multinational pharmaceutical company. Bayer AG is publicly traded under the ticker symbol BAYRY.
Hydrocortison is in Phase 2 clinical development for atopic dermatitis. It is an investigational drug and has not been approved by regulatory authorities. One Phase 2 trial has been completed.
Hydrocortison has one completed Phase 2 clinical trial, identified as NCT00980135, titled 'Sinecort Pilot Efficacy Study'. This trial enrolled 40 participants with atopic dermatitis in Germany and was a controlled, randomized study.
Hydrocortison is associated with the trial title 'Sinecort Pilot Efficacy Study', which suggests that Sinecort may be an alternative name for the drug. The trial NCT00980135 is the only clinical trial listed for this drug.